IceCure Medical Ltd (ICCM)

IceCure Medical Ltd. focuses on cryoablation technology for tumor treatment, primarily with its ProSense system for breast cancer. The company is based in Israel and operates in the medical device industry.

45/100 AI Score MCap 45M Vol 205K

Company Overview

CEOEyal Shamir
Employees64
HeadquartersCaesarea, IL
IPO Year2021

IceCure Medical pioneers minimally invasive cryoablation solutions with its ProSense system, targeting the growing market for tumor treatment, particularly breast cancer, offering a compelling alternative to traditional surgery and positioning the company for significant growth in the medical device sector.

Investment Thesis

IceCure Medical presents a compelling investment opportunity due to its innovative ProSense cryoablation system and its potential to disrupt the tumor treatment market. The company's focus on minimally invasive procedures aligns with the growing demand for less invasive treatment options, particularly in breast cancer. With a market capitalization of $0.04 billion, IceCure offers significant upside potential as it expands its product applications and secures further regulatory approvals. Key value drivers include the increasing adoption of cryoablation technology, successful clinical trial outcomes, and strategic partnerships to expand market reach. The company's gross margin of 35.1% indicates a solid foundation for profitability as revenue scales. Upcoming catalysts include potential FDA approvals for expanded indications and positive clinical data releases, positioning IceCure for substantial growth in the coming years.

Key Highlights

  • Market Cap of $0.04B indicates a small-cap company with potential for high growth.
  • Gross Margin of 35.1% demonstrates the company's ability to generate profit from its sales.
  • Beta of 2.21 suggests the stock is more volatile than the market, offering potential for higher returns but also higher risk.
  • The company's focus on cryoablation technology positions it in a niche market with growing demand for minimally invasive tumor treatments.
  • The ProSense system is a key differentiator, offering a non-surgical alternative for breast tumor treatment.

Competitors

Strengths

  • Innovative ProSense cryoablation system.
  • Minimally invasive treatment approach.
  • Focus on breast cancer treatment.
  • Strong intellectual property protection.

Weaknesses

  • Limited market share compared to established players.
  • Negative profit margin.
  • High beta indicates high volatility.
  • Reliance on a single product line.

Catalysts

  • Upcoming: Potential FDA approvals for expanded indications of the ProSense system.
  • Upcoming: Positive clinical trial data releases demonstrating the efficacy of cryoablation for various tumor types.
  • Ongoing: Increasing adoption of cryoablation technology by healthcare providers.
  • Ongoing: Strategic partnerships with hospitals and clinics to expand market reach.

Risks

  • Potential: Competition from established players in the tumor ablation market.
  • Potential: Regulatory hurdles and approval delays for new products and indications.
  • Potential: Reimbursement challenges from healthcare providers for cryoablation procedures.
  • Ongoing: The company's negative profit margin poses a risk to its financial sustainability.
  • Ongoing: High beta indicates high volatility, which can lead to significant price fluctuations.

Growth Opportunities

  • Expansion into New Tumor Types: IceCure has the opportunity to expand the application of its ProSense system beyond breast cancer to treat other types of tumors, such as kidney, lung, and liver tumors. This expansion would significantly increase the addressable market and drive revenue growth. The market for ablation of these other tumor types is substantial, potentially adding hundreds of millions of dollars in revenue over the next 3-5 years.
  • Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with hospitals, clinics, and distributors can accelerate the adoption of the ProSense system and expand IceCure's market reach. Collaborating with established players in the medical device industry can provide access to new markets and distribution channels. These partnerships could lead to a significant increase in sales volume within the next 2-3 years.
  • Securing Regulatory Approvals in New Markets: Obtaining regulatory approvals in key international markets, such as Europe and Asia, is crucial for expanding IceCure's global footprint. These approvals would allow the company to market and sell its ProSense system in these regions, opening up new revenue streams. The timeline for securing these approvals is typically 1-2 years per region.
  • Development of Next-Generation Cryoablation Technologies: Investing in research and development to develop next-generation cryoablation technologies can enhance IceCure's competitive advantage and attract new customers. This includes developing more advanced freezing techniques, improved imaging guidance, and enhanced user interfaces. The development of these technologies could lead to a new product line within the next 3-5 years.
  • Increased Awareness and Education: Implementing marketing campaigns to raise awareness of the benefits of cryoablation and the ProSense system among physicians and patients can drive adoption and increase sales. Educating healthcare professionals about the advantages of cryoablation over traditional surgical procedures can lead to greater acceptance and utilization of the technology. These campaigns can start immediately and show results within 1 year.

Opportunities

  • Expansion into new tumor types.
  • Strategic partnerships and distribution agreements.
  • Securing regulatory approvals in new markets.
  • Development of next-generation cryoablation technologies.

Threats

  • Competition from alternative ablation technologies.
  • Regulatory hurdles and approval delays.
  • Reimbursement challenges from healthcare providers.
  • Potential for product liability claims.

Competitive Advantages

  • Proprietary cryoablation technology with patents protecting the ProSense system.
  • Established clinical data supporting the safety and efficacy of the ProSense system.
  • First-mover advantage in the cryoablation market for breast cancer treatment.
  • Strong relationships with key opinion leaders in the medical community.

About

IceCure Medical Ltd, established in 2006 and headquartered in Caesarea, Israel, is a medical device company dedicated to the research, development, and commercialization of advanced cryoablation technologies. The company's core innovation lies in its ProSense system, a minimally invasive solution designed for the cryoablation (freezing and destruction) of tumors. Initially focused on breast cancer treatment, IceCure's ProSense system offers a compelling alternative to traditional surgical procedures, providing a less invasive option for patients. The system utilizes liquid nitrogen to precisely freeze and eradicate targeted tumor cells, minimizing damage to surrounding healthy tissue. IceCure's strategic focus is on expanding the applications of its cryoablation technology to treat various types of tumors throughout the body. The company has been actively pursuing regulatory approvals and clinical trials to broaden the use of ProSense and explore new market opportunities. With a commitment to innovation and patient-centric solutions, IceCure Medical aims to establish itself as a leader in the field of cryoablation, transforming the landscape of tumor treatment and improving patient outcomes. The company's commitment to research and development ensures a pipeline of innovative solutions that address unmet needs in the medical field.

What They Do

  • Develops and commercializes cryoablation medical devices.
  • Offers the ProSense system for freezing and destroying tumors.
  • Focuses on minimally invasive tumor treatment solutions.
  • Provides an alternative to traditional surgical procedures.
  • Targets breast cancer as a primary application.
  • Conducts research and clinical trials to expand product applications.
  • Seeks regulatory approvals for its devices in various markets.

Business Model

  • Sells the ProSense cryoablation system to hospitals and clinics.
  • Generates revenue from the sale of disposable cryoprobes used with the system.
  • Provides training and support services to healthcare professionals.
  • Pursues strategic partnerships for distribution and market expansion.

Industry Context

IceCure Medical operates within the medical device industry, specifically targeting the market for tumor ablation technologies. The industry is experiencing growth driven by increasing cancer incidence and a growing preference for minimally invasive procedures. The competitive landscape includes companies offering alternative ablation methods such as radiofrequency ablation and microwave ablation. IceCure's ProSense system differentiates itself through its cryoablation technology, which offers precise and controlled freezing of tumors. The global market for tumor ablation is projected to reach billions of dollars in the coming years, presenting a significant opportunity for IceCure to expand its market share.

Key Customers

  • Hospitals and medical centers.
  • Oncology clinics.
  • Breast cancer treatment centers.
  • Radiology departments.
AI Confidence: 71% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $850,000 -$4M $0.00
Q2 2025 $525,000 -$3M $0.00
Q1 2025 $725,000 -$4M $0.00
Q4 2024 $875,000 -$4M $0.00

Source: Company filings

Chart & Info

Price Chart

IceCure Medical Ltd (ICCM) stock price: $0.65 (+0.02, +3.17%)

Why Bull

  • •Recent insider buying indicates confidence in the company's future, suggesting positive expectations among key stakeholders.
  • •Community sentiment has shifted favorably, with increasing discussions around IceCure's innovative technologies and their potential impact on the market.
  • •Recent developments in clinical trials have garnered attention, highlighting the efficacy of their treatments and attracting interest from healthcare professionals.
  • •Strategic partnerships are being formed, enhancing their market presence and signaling growth opportunities in the medical sector.

Why Bear

  • •Concerns about regulatory hurdles persist, as navigating the medical approval landscape can be lengthy and unpredictable.
  • •Some community members express skepticism regarding the scalability of IceCure's technologies, questioning their adoption in broader healthcare settings.
  • •Market competition is intensifying, with new entrants potentially overshadowing IceCure's offerings and impacting market share.
  • •Recent volatility in healthcare stocks has led to cautious sentiment, with investors wary of overexposure in this sector.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
204,476

Rationale

AI-generated technical analysis for ICCM including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss IceCure Medical Ltd (ICCM) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for ICCM.

Make a Prediction

Set your price target for IceCure Medical Ltd (ICCM), choose a timeframe, and track your prediction accuracy.

Current price: $0.65

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ICCM.

Price Targets

Wall Street price target analysis for ICCM.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

44.5/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 1.9% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 6/100

    Gross margin of 35.1% is acceptable but leaves limited room for R&D and marketing investment.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates ICCM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does IceCure Medical Ltd do?

IceCure Medical Ltd is a medical device company specializing in cryoablation technology. Its primary product, the ProSense system, is designed for the minimally invasive freezing and destruction of tumors. The company focuses on providing an alternative to traditional surgical procedures, particularly in the treatment of breast cancer. IceCure's business model involves selling the ProSense system and related disposable cryoprobes to hospitals and clinics, along with providing training and support services. The company aims to expand its market reach through strategic partnerships and regulatory approvals in new markets.

Is ICCM stock a good buy?

ICCM stock presents a speculative investment opportunity with high potential but also significant risk. The company's innovative ProSense system and focus on minimally invasive tumor treatment are promising, but its negative profit margin and high beta indicate financial instability and volatility. Investors should carefully consider the company's growth prospects, potential regulatory hurdles, and competitive landscape before investing. While the company's market capitalization of $0.04 billion suggests significant upside potential, the risks associated with its financial performance and market position should not be overlooked. A balanced approach is necessary when evaluating ICCM stock.

What are the main risks for ICCM?

The main risks for IceCure Medical Ltd include intense competition from established players in the tumor ablation market, potential regulatory hurdles and approval delays for new products and indications, and reimbursement challenges from healthcare providers for cryoablation procedures. The company's negative profit margin poses a significant risk to its financial sustainability, and its high beta indicates high volatility, which can lead to significant price fluctuations. Additionally, the company's reliance on a single product line makes it vulnerable to market shifts and technological advancements. Investors should carefully assess these risks before investing in ICCM stock.

Is ICCM a good stock to buy?

Whether ICCM is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the ICCM MoonshotScore?

The MoonshotScore for ICCM is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is ICCM data updated?

ICCM stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ICCM is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for ICCM?

Growth catalysts for IceCure Medical Ltd (ICCM) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes IceCure Medical Ltd's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are ICCM's main competitors?

IceCure Medical Ltd (ICCM) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ICCM has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about ICCM?

Wall Street analyst coverage for ICCM includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is ICCM's market cap?

Market capitalization (market cap) for ICCM is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ICCM's current market cap alongside enterprise value and other valuation metrics.

How has ICCM stock performed recently?

ICCM's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ICCM's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in ICCM?

Key risk categories for ICCM include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ICCM's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling ICCM?

Insider trading activity for ICCM tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is ICCM a good stock for beginners?

IceCure Medical Ltd (ICCM) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is ICCM for first-time investors?

Every stock carries risk, including IceCure Medical Ltd (ICCM). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ICCM.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment decisions should be made based on individual risk tolerance and financial circumstances.
Data Sources
profilefundamentalsexistingCopy